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Once the seeds are formed, they rapidly grow by incorporating monomeric protein into the polymer 13, 15 . Large polymers can fragment in a process not well-known in vivo to generate more seeds to propagate the reaction. A typical feature of the seeding-nucleation model is the ability of preformed seeds to greatly accelerate the aggregation process by recruiting the soluble normal protein into the growing aggregate 13, 15 . From a biophysical viewpoint, the process of protein misfolding and aggregation involves rearranging the structure of the protein into a series of β -strands. These strands are stabilized by hydrogen bonding and hydrophobic interactions and open up 'sticky' ends for attracting molecules of the folded or partially unfolded protein, forcing its misfolding to fit into the cross-β polymeric structure. Although the primary scaffold of the misfolded aggregates is similar, the individual molecules can adopt many quite varied structures, which give rise to the possibility of conformational strains, as discussed below.
Despite the commonalities in the pathological mechanisms of NDs, there are some important differences among the distinct diseases: clinical symptoms, prevalence, risk factors, areas of the brain affected, cellular types injured, and genes implicated. In addition, each ND is usually associated with the misfolding and aggregation of a distinct protein that forms deposits that accumulate in diverse cellular locations, including the cytoplasm, nucleus, plasma membrane, or extracellular spaces. Finally, although the gross structural signature of the aggregates is similar (the cross-β conformation), their detailed structure is likely very different depending on the protein and the disease. The dissimilarities in the protein sequence, cellular location, and biophysical nature of the aggregates probably determine that the mechanisms of cellular toxicity are also different.
the prion principle and its role in neurodegenerative diseases
The seeding property, common to all misfolded protein aggregates, confers on them the inherent ability to spread the misfolding and aggregation process in a manner akin to infectious prion particles 15, 16 . PrDs are the only NDs convincingly demonstrated to be transmissible by infection 16, 17 . The infectious agent, termed a prion, is composed exclusively of misfolded prion protein (PrP Sc ) aggregates that self-replicate in the infected brain 18, 19 . Disease transmission is mediated by prion aggregates acting as seeds to initiate the misfolding and aggregation of the native, monomeric prion protein in the host 16 .
At some point, the long polymers undergo fragmentation to release more seeds, increasing the rate of prion propagation. In accordance with the seeding-nucleation model, PrP Sc silently propagates for a long period of time until reaching the toxic threshold necessary for cellular dysfunction, brain damage, and clinical disease 16 .
The fact that seeding of protein aggregation is a common feature of all misfolded proteins implicated in NDs suggests that they have the potential to behave as prions 15 . This concept was initially taken with some reticence, despite the fact that it was supported by various previous articles showing evidence for pathological transmission of protein deposits in diverse forms of systemic amyloidosis 20, 21 . In recent years, the concept that misfolded protein aggregates can spread pathologically by the prion principle has steadily gained acceptance in the field. Indeed, a series of reports have demonstrated that several NDs can be experimentally transmitted by a prion-like mechanism in various cellular and animal models of diverse diseases 3, 16, 22, 23 . Studies with Aβ , tau, and α -Syn have shown that inoculation with tissue homogenates from patients affected by NDs or transgenic mouse models rich in protein aggregates results in the induction of disease pathology in the recipient cellular or animal models 3, 16, 22, 23 . Moreover, in animals not genetically programmed to develop the disease spontaneously, pathological induction has been demonstrated to result in a completely de novo disease, more akin to infectious prions [24] [25] [26] . Pathological induction can be reduced by depleting the inoculum of protein aggregates [27] [28] [29] , and transmission has been achieved by adding misfolded protein aggregates prepared in vitro using synthetic or recombinant components [30] [31] [32] [33] . However, in general, transmission using tissue homogenates is more efficient than with purified proteins, suggesting that other cellular cofactors may play a role in the pathological induction 22, 34 . Accumulation of protein aggregates can be promoted by inoculation of small amounts of aggregated seeds 35, 36 , and in some cases titration experiments have been done to show that the rate of induction is proportional to the amount of seed inoculated 35 . Finally, disease transmission has been observed even when seeds were administered systemically 37, 38 . An open and controversial issue is whether spreading of protein misfolding is equivalent to spreading of disease. In some cases, the pathological induction is restricted to the accumulation of protein aggregates, and in others it is accompanied by tissue damage and clinical signs typical of the disease. These findings suggest that promoting protein misfolding not only leads to increased protein aggregation, but also accelerates the whole disease. It is also important to highlight that induction is not always expected to result in very obvious clinical signs leading to rapid death as in PrD. For example, in AD, the expected clinical phenotype is characterized by subtle memory and cognitive changes that can only be detected in rodents by sophisticated behavioral tests.
These findings support the concept that many of the hallmark properties of prions as infectious agents are shared by the main proteins involved in NDs. Still, the main controversial point is whether other misfolded proteins can act as infectious agents to transmit the disease among individuals under natural conditions 17, 39, 40 . However, it is important to note that even some typical PrDs are not naturally infectious and infectivity has only been supported by laboratory experiments 41 . Also, other PrDs are transmissible only in certain rare conditions, and tracking the infectious origin is often difficult because of the usually long time between infection and development of clinical symptoms 16 . Finally, it is important to highlight that transmission of biological information via prions by seeding of protein aggregation operates at multiple levels 42, 43 (Fig. 1) . At the molecular level, the template-induced conversion of the natively folded protein by the polymeric misfolded protein leads to autocatalytic growth of protein aggregates. At the cellular level, the pathology spreads from cell to cell through the transfer of misfolded protein aggregates between adjacent cells, leading to regional spreading of the abnormalities. At the organ level, the progressive 
Seeding of new fibrils
Brain region-to-brain region spreading Fig. 1 | Protein aggregation and the prion principle of pathological transmission. Monomeric proteins can misfold and aggregate. Spreading of protein misfolding operates at different levels during the pathogenesis of NDs, including molecule-to-molecule, cell-to-cell and brain region-to-brain region. In some specific cases, it may also operate to transmit the disease from individual to individual, as has been demonstrated for PrDs.
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Review ARticle | FOCUS NATuRe NeuRosCIeNCe spreading of the pathology among cells leads to tissue damage that can be transmitted to remote or distant areas of the brain, either by cell-to-cell contact or through biological fluids, such as interstitial fluid, cerebrospinal fluid, or blood. At the organismal level, exposure of a naive individual to misfolded aggregated seeds can initiate the process of protein misfolding, leading to disease in an infectious manner. It seems likely that in some NDs, the prion principle may operate only at the molecular, cellular, and tissue levels to spread the pathology, thus playing a key role in disease progression ( Fig. 1 ). Currently, it is controversial whether transmission at all these levels is required before other misfolded proteins can be considered a 'bona fide' prion. In this sense, it might be necessary to update the definition of the word prion to refer to proteins able to adopt alternative conformations, some of which can self-propagate their folding in an autocatalytic seeding reaction that can be spread between cells and tissues.
the polymorphic nature of misfolded proteins and the concept of conformational strains
Misfolded protein aggregates consist of a heterogeneous mixture of different species, differing in size and structure 12, 44, 45 . In PrDs, the structural heterogeneity of protein aggregates has resulted in the ability of PrP Sc to self-propagate distinct 'conformational variants' that can result in diseases with different characteristics. These conformational variants are often referred to as prion strains, analogous to strains of conventional infectious agents [46] [47] [48] . Different prion strains can perpetuate their properties indefinitely at the expense of the same normal prion protein, a process reproduced in a cell-free system in vitro 49 . The absence of high-resolution structural information for PrP Sc has limited our understanding of the biophysical bases of prion strains 50 . Several studies have reported evidence for the existence of conformational strains for misfolded aggregates composed of Aβ 51-54 , tau [55] [56] [57] , and α -Syn 58-61 . These findings may account for the large heterogeneity of AD and PD and may provide a molecular explanation for distinct tauopathies 57 and synucleinopathies 62 (Fig. 2) . Indeed, there are at least seven different diseases associated with the accumulation of tau aggregates, including AD, frontotemporal dementia, progressive supranuclear palsy, corticobasal degeneration, argyrophilic grain disease, and chronic traumatic encephalopathy 63 , and three involving α -Syn deposition, including PD, multiple system atrophy, and Lewy body dementia 64 . As in PrDs caused by distinct prion strains, different tauopathies and synucleinopathies can be distinguished by the clinical symptoms, brain-region-specific pathology, and preference of the aggregates to accumulate in different cell types and/or by the distinct morphological and biophysical characteristics of the aggregates, their toxicity, and their seeding ability [63] [64] [65] .
One study isolated and characterized 18 different tau strains in a cell culture model, each of which differed in various biochemical and biological properties 55 . Inoculation of transgenic mice with these strains produced strain-specific intracellular tau aggregates in distinct cell types and brain regions, which showed different rates of propagation 55 . These findings suggest that different tau species can self-propagate, leading to diverse neuropathological presentations, some reminiscent of those found in human tauopathies. In support of this conclusion, different tau strains were isolated from 29 patients affected by five distinct tauopathies, suggesting that diverse tauopathies are associated with different sets of conformational strains 56 . Cryo-electron microscopy has enabled the construction of atomic models of tau aggregates organized either as paired helical or straight filaments 66 . Filaments are made of two identical protofilaments spanning residues 306-378 of tau, which adopt a combined cross-β -β -helix structure. Paired helical and straight filaments differ in their inter-protofilament packing, providing a model to explain how the same protein can adopt different conformational variants.
Similarly, α -Syn assemblies displaying different structural characteristics have been shown to self-propagate in vivo, leading to distinct histopathological and behavioral phenotypes, some similar to those observed in different human synucleinopathies 58, 60, 61 . Inducing α -Syn aggregation in vitro in the presence of distinct concentrations of salts results in either cylindrical fibrils or flat, twisted ribbons 61 . These alternative structures were characterized in detail, showing profound differences with regards to proteolytic resistance, secondary structure, X-ray fiber-diffraction patterns, distribution of secondary structure elements determined by solid-state NMR, cellular toxicity, in vitro seeding, and propagation in mammalian cells.
In contrast to tau and α -Syn, which accumulate in diverse NDs, Aβ deposition occurs mostly in the brain of AD patients. Nevertheless, Aβ deposits are also highly heterogeneous, appearing in the form of mature dense-core plaques, diffuse deposits, cerebral amyloid angiopathy, inert deposits, and intracellular aggregates 67 . Several lines of evidence have shown that Aβ can also adopt different conformational strains, which may explain the heterogeneity observed in the patients' brains. Studies by electron microscopy, atomic force microscopy, and solid-state NMR have revealed that Aβ can aggregate into multiple conformations in vitro 52,68-70 . High-resolution structural studies demonstrate that different experimental conditions can generate synthetic Aβ aggregates with substantially distinct structures 52 . Specifically, Aβ 40 fibrils grown at 24 °C and pH 7.4 with gentle agitation have a predominantly 'striated-ribbon' morphology, whereas fibrils grown under the same conditions except without agitation have a predominantly 'twisted' morphology. The main biophysical difference between the two types of fibrils is their overall symmetry, with the striated ribbon filaments containing two cross-β subunits related by approximately two-fold rotational symmetry about the fibril growth axis and the twisted fibrils containing three cross-β units related by approximately three-fold rotational symmetry. These conformers were able to faithfully template their structure upon seeding of monomeric Aβ peptides in vitro over multiple rounds of self-propagation. In a similar manner, seeding experiments with Aβ aggregates obtained from the brains of patients affected by diverse clinicopathological AD phenotypes resulted in structurally distinct synthetic Aβ fibrils 53, 71 , providing additional evidence for the existence of biologically relevant Aβ strains.
Molecular cross-talk among misfolded proteins through cross-seeding
Misfolded protein aggregates normally grow at the expense of proteins that can establish identical or highly complementary interactions and, thus, usually have the same or very similar amino acid 65 . This process, often referred to as heterologous seeding or cross-seeding ( Fig. 3 ), has been extensively described using pure preparations of proteins in test tube experiments [72] [73] [74] [75] [76] [77] [78] . The direct interaction leading to hybrid polymers initiated by seeds composed of one protein growing at expense of a second protein has been demonstrated by biophysical studies using immune-electron microscopy, co-immunoprecipitation, molecular modeling, and atomic force microscopy. The co-existence of two or more different types of protein aggregates in various NDs has been extensively reported [79] [80] [81] [82] [83] [84] . The archetypal case is AD, which simultaneously exhibits intracellular tau neurofibrillary tangles and extracellular Aβ amyloid plaques 85 .
Although it is possible that tangles and plaques are formed independently, several studies have provided evidence for misfolded Aβ promoting tau abnormalities, perhaps by a direct protein-protein interaction [86] [87] [88] [89] [90] . Neuropathological studies have shown that nearly half of AD cases also display some α -Syn deposition 82, 91 and/ or TDP-43 aggregates 92 . In PD and related synucleinopathies, the frequency of mixed pathology is even higher, with approximately 80% of the cases showing detectable Aβ deposits, 50% showing tau aggregates, and 30% showing TDP-43 deposition 82 . The large pathological overlap between protein aggregates in the same brain complicates diagnosis and treatment and raises the question of which is the predominant disease. Based on pathological analysis and clinical progression, it seems that the disease is initiated by one type of protein aggregate, which acts as the driving force and defines the initial manifestation of the clinical phenotype, but later leads to the accumulation of other protein aggregates that come as secondary products and may change or expand the clinical picture 82 . An illustrative case for this concept is PD, which begins with classical motor symptoms, but over time a large proportion of the patients develop dementia 93, 94 . It is tempting to speculate that the symptoms of dementia may be caused by the onset of AD-like protein aggregates 95, 96 , but it is important to note that deposition of α -Syn aggregates in certain areas of the brain can also lead to dementia on its own, as happens in dementia with Lewy bodies 97, 98 .
It is important to highlight that, although a direct interaction between misfolded proteins through cross-seeding is supported by in vitro experiments, there are various other alternative explanations for the synergistic interaction between diverse NDs. Alternative pathways to cross-seeding include enhancement of cellular vulnerability, impairments in clearance machinery, brain inflammation, and triggering of indirect signal transduction pathways resulting in increase of protein misfolding 84 . It is also important to consider that some properties attributed to seeding or cross-seeding, such as the stereotypical progression of pathology observed in some NDs, might be also explained by selective neuronal vulnerability 99 .
Protein aggregation in NDs might be also cross-seeded by seeds from systemic disorders associated with protein aggregation in peripheral tissues. Perhaps the best supported case for this mechanism is the interaction between AD and type-2 diabetes (T2D). T2D is associated with the pancreatic accumulation of the islet amyloid polypeptide (IAPP). Interestingly, T2D patients exhibit an increased risk of developing AD 100, 101 , while approximately 80% of AD patients develop T2D or abnormalities in glucose metabolism 102 . Transgenic animals expressing both human Aβ and IAPP exhibit exacerbated AD-like pathology 77 . IAPP colocalizes with amyloid plaques in brain parenchymal deposits 77, 103 , suggesting that these peptides may directly interact and aggravate the disease. Furthermore, inoculation of pancreatic IAPP aggregates into the brains of AD transgenic mice resulted in more severe AD pathology and substantially greater memory impairments than untreated animals 77 . The cross-seeding mechanism was supported by in vitro experiments showing that IAPP seeds can accelerate Aβ aggregation and that both peptides were found forming part of the same fibrils 77, 103 .
Finally, an emerging possibility is that pathological aggregates responsible for NDs may be induced by seeds from 'functional amyloids' 16, 104 . In recent years, several proteins have been shown to naturally aggregate into nonpathogenic amyloid structures that contribute to modulating protein function or even acquire a new biological activity. These functional amyloids have been described in organisms ranging from bacteria to humans 16, [105] [106] [107] , indicating that formation of these structures is not necessarily a pathological process. The possibility that protein misfolding and aggregation leading to NDs may be initiated by cross-seeding with functional amyloids has not been explored in detail 16, 104 . However, a recent study reported that bacterial amyloids may play a role in α -Syn aggregation 108 .
implications for therapy
Despite the extensive knowledge of the molecular mechanisms implicated in NDs, no cures or efficient treatments are yet available for these diseases. Misfolded protein aggregates are a primary target for therapeutic intervention. The recent discoveries of prion-like behavior, strain variability, and molecular cross-talk between different amyloidogenic proteins have uncovered both new therapeutic targets ( Fig. 4 ) and potential unexpected difficulties.
A primary strategy includes eliminating the source of exogenous seeds to which an individual may be exposed to (Fig. 4a ). Although it is highly controversial whether NDs other than PrDs can be acquired by an external infectious process 17, 39, 40, 109 , if this is proven for a portion of cases, reducing the risk of exposure will make a good strategy for preventing new cases. This approach has proven successful for PrDs. For example, the dramatic reduction of bovine spongiform encephalopathy by changing cattle feeding practices minimized human exposure and decreased the risk of variant CJD 110 .
Several approaches are under development to prevent the formation of or to remove misfolded aggregates (Fig. 4b) . Targeting specifically the misfolded aggregates most competent for seeding might be a good approach for treatment, since these structures are likely less abundant than the normal protein or the fully aggregated material deposited in the brain. Various oligomer-specific antibodies and small molecules have already shown efficacy in animal models of 
Fig. 3 | Cross-seeding interactions between diverse misfolded protein aggregates.
In vitro and in vivo experiments have shown that aggregates composed of one protein usually seed the aggregation of the same protein (homologous seeding). However, in some circumstances, an aggregate may also seed the aggregation of a different protein, in a process termed heterologous seeding or cross-seeding. Cross-seeding events may explain the frequent finding of mixed pathologies in which more than one misfolded protein aggregate is found in a patient brain. 111 ). Elucidation of the threedimensional structure of oligomeric seeds may contribute substantially to the rational design of strategies targeting these species. Cellular pathways implicated in the spreading of seeds can also be targeted (Fig. 4c) . The exact mechanisms involved in the cell-tocell spreading of misfolded seeds are not known, but several cellular pathways have been proposed [112] [113] [114] , including trans-synaptic transport, exocytosis and endocytosis, transfer through tunneling nanotubes, transport through exosomes, and direct protein-protein interactions at the cell surface. In theory, targeting various routes implicated in the transfer of seeds between cells might be an efficient approach for treatment. However, since these are general cellular processes, it is likely that manipulating them may produce side-effects.
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The elongation and multiplication of seeds can also be arrested (Fig. 4d ). The process of protein misfolding and aggregation depends on elongation and subsequent fragmentation of polymers to release more seeds. A good strategy for inhibiting elongation could be capping the seeds with molecules that prevent the incorporation of new monomers. The factors and forces involved in fragmentation of aggregates could also be manipulated to prevent the generation of additional seeds from an elongating protein aggregate. Although most fragmentation factors remain unknown, the yeast chaperone protein HSP104 has been shown to have this activity, and its inhibition cures yeast of prion infection 115 . Future research should aim to identify the HSP104-like factors operating in the human brain.
The prion principle can also be used to guide the development of antiprion therapeutic molecules (Fig. 4e ). An important challenge for effectively attacking the prion-like spreading of protein misfolding and aggregation is that this process grows exponentially over time. We recently proposed utilizing the prion principle to generate a self-replicating therapy that could effectively outcompete with prion-like misfolded proteins 116 . The idea is to dissociate seeding from toxicity of the aggregated product, by generating a conformational strain that can efficiently seed and spread but result in the formation of innocuous material. Since both pathogenic seeds and therapeutic antiprions utilize the same monomeric protein to grow, antiprions will progressively deplete the substrate for seeding, thus delaying the accumulation of pathological misfolded proteins.
A single prophylactic inoculation of prion-infected animals with an in vitro-generated antiprion delayed the onset of the disease and, in some animals, completely prevented the development of clinical symptoms and brain damage 116 . In this approach, the therapeutic molecule self-replicates in the body, outcompeting the pathogenic process. Extrapolation of this concept to other misfolded proteins may result in a universal approach for treatment of NDs by employing the prion principle to generate a self-replicating therapy targeted to each protein.
The recognition of the prion principle and its associated features poses some previously unappreciated difficulties for therapeutic interventions. For example, the large diversity of conformational strains that each misfolded protein can adopt make it challenging to identify molecules that will target all of them at the same time. Therefore, compounds may be efficient for only a subgroup of patients or a subset of pathological structures in the brain. Also, a well-established property of prion strains is their ability to change and mature over time, leading to changes in their properties 47, [117] [118] [119] . In particular, it has been shown that prions can acquire drug resistance after prolonged treatment with a therapeutic molecule 120, 121 . The phenomena of cross-seeding and mixed pathologies represent an additional difficulty for treatment. In fact, pharmacological inhibition of one misfolded protein aggregate may enhance crossseeding events that result in the accumulation of a different type of aggregate. Thus, in patients harboring different types of protein aggregates in their brains, elimination of one of them may simply switch the clinical phenotype, but not eliminate the disease.
implications for early diagnosis
Difficulties achieving therapeutic benefits in NDs can largely be attributed to the lack of diagnostic tools necessary for early identification of the disease before it destroys irreversibly the brain 122 . Today, all NDs are diagnosed by clinical examination with the help of imaging techniques 123 . The problem is that clear clinical symptoms are evident only after substantial damage to the brain, an organ that does not repair very well after injury. Extensive efforts are ongoing to identify biomarkers circulating in biological fluids that can be used for early, sensitive, objective, and noninvasive biochemical diagnosis of NDs 124 .
Several lines of evidence indicate that the process of misfolding and oligomerization in NDs begins years or even decades before these aggregates become massively deposited in the brain and induce the onset of brain damage and clinical symptoms 125, 126 . Considering that soluble misfolded oligomers are the most likely culprits of neurodegeneration and pathological spreading, their sensitive detection might represent a great strategy for early and specific biochemical diagnosis of various NDs 125 . Moreover, various Review ARticle | FOCUS
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NATuRe NeuRosCIeNCe studies have shown that misfolded oligomers composed of different proteins are naturally secreted by cells and circulate in diverse biological fluids 125, 127, 128 . However, the challenge for detecting misfolded oligomers is that they are highly heterogeneous, are present in very low concentrations in biological fluids, and have the same sequence as the more abundant natively folded protein 125 . Nonetheless, various strategies have been proposed to specifically detect misfolded oligomeric forms of proteins associated to NDs (Fig. 5 ) 125 , such as enzyme-linked immunosorbent assay (ELISA)-based techniques in which oligomers are detected by using oligomer-specific conformational antibodies 129 ; alternative ELISA strategies including conjugation with short oligonucleotides using the proximity-ligation assay 130 or double usage of the same sequence-specific antibody twice in the system, for capturing as well as for detection 131 ; methods for single-particle detection, such as fluorescence correlation spectroscopy 132 , flow cytometry 133 , and laser scanning microscopy 134 ; and biosensor techniques employing surface plasmon resonance 135 or electrochemical impedance spectroscopy 136 sensors combined with oligomer-specific recognition methods. Another diagnostic strategy is to use the prion principle of spreading by seeding to amplify the misfolding and aggregation process in vitro. Two closely related seeding amplification assays have been employed for this purpose: protein misfolding cyclic amplification (PMCA) 137, 138 and real-time quaking-induced conversion (RT-QuIC) 139 . Both techniques use a system for cyclic amplification done in two phases. During the first phase, minute amounts of seeding-competent, misfolded oligomers from the patient's samples are incubated with native protein substrate to induce the misfolding via polymer growth. In the second phase, the sample is subjected to mechanical fragmentation of the polymers (for example, sonication or strong shaking), multiplying the number of seeding-competent nuclei 138 . After each cycle, the number of seeds increases in an exponential fashion. The PMCA and RT-QuIC techniques were initially applied to amplify and detect PrP Sc implicated in PrDs 137, 140 . Using PMCA, the equivalent of a single particle of misfolded PrP oligomers can be detected 141 , and PrP Sc can be identified in the blood and urine of people suffering from CJD [142] [143] [144] . PMCA and RT-QuIC are currently being routinely used in the USA and Europe to help in diagnosing CJD. Recently, the seeding amplification technology was extended to detect seeding-competent Aβ 145 , tau 146 , and α -Syn 147, 148 , oligomers circulating in the cerebrospinal fluid of patients affected by AD, tauopathies, and PD, respectively. The technology successfully enabled detection with high sensitivity and specificity for patient samples as compared to controls affected by other NDs or neurological disorders. More research is necessary to evaluate the reproducibility, sensitivity, and specificity of seeding amplification assays and their application to monitor disease progression and preclinical diagnosis. Potential caveats of these technologies are the possibility for false-positive results due to contamination or crossseeding events.
Future perspectives
Despite the impressive knowledge accumulated, NDs remain incurable. The prevalence of NDs continues to increase, and they have become one of the largest public health problems. There is a wide consensus that the key event common to all NDs is the misfolding, oligomerization, and progressive accumulation of proteins in the brain. A recent breakthrough was the discovery that misfolded protein aggregates can self-propagate their pathological properties using the prion principle of transmission of biological information by seeding of protein misfolding. This discovery has vast implications for understanding the mechanisms involved in the initiation and progression of NDs as well as for the design of novel strategies for treatment and diagnosis. It also sheds light on the great challenges that therapeutic strategies will face to produce a beneficial outcome for patients.
There are still many important open questions in relation to the role, mechanism, features, and implications of prion-like spreading of misfolded protein aggregates in NDs (Box 1). Considering the expansion of the prion concept in recent years, it may be necessary to implement a more modern definition of prions along the lines of 'proteinaceous nucleating particles' 22 . In this article, we propose to
Box 1 | open questions regarding the prion-like phenomenon in neurodegenerative diseases

Role of prion-like propagation in NDs
Are misfolded protein aggregates the direct cause of NDs? What type(s) of misfolded, aggregated species are responsible for neurodegeneration? What is the role of prion-like spreading in the progression of NDs? How are the first seeds generated in the body? Can other NDs be transmitted by infection like PrDs? Does the prion principle operate in all diseases associated with misfolded protein aggregates as well as in functional amyloids?
Mechanisms of prion-like spreading
By which routes and practices can misfolded seeds be acquired in NDs? Is there any role for peripheral replication of prion-like proteins in NDs? Can other species of animals produce misfolded protein aggregates that can seed the pathological process in humans (similarly to how bovine spongiform encephalopathy triggers variant CJD in PrDs)? What are the cellular pathways implicated in prion-like spreading of protein aggregates? Which processes and factors are responsible for the fragmentation of polymers leading to multiplication of seeds? What is the detailed molecular mechanism for templated conversion of the normal protein into the misfolded form? Which of the aggregated species are the most efficient in seeding? What is the three-dimensional structure of oligomeric seeds?
Conformational prion strains
How many conformational variants can a single misfolded protein adopt? Are there other factors necessary for the formation of prion-like strains? What are the structural differences between strains? How can different conformational strains target distinct areas of the brain? Do prion-like strains mature, change, and adapt depending on the conditions of the host? Can conformational variants undergo strain selection to develop resistance to drug treatment? Are different prion-like strains responsible for the diverse clinical phenotypes of NDs? Are different tauopathies and synucleinopathies caused by distinct conformational strains of tau and α -Syn? Are Aβ strains responsible for the heterogeneous accumulation of different types of protein deposits commonly observed in AD brains?
Cross-seeding and mixed pathology
What is the role of cross-seeding in the pathogenesis of NDs? Is mixed pathology caused by cross-seeding events? Which combination of misfolded proteins results in cross-seeding or cross-inhibition of protein misfolding? Can misfolded protein aggregates in the brain be promoted by cross-seeding from systemic amyloid diseases? Are functional amyloids involved in initiating ND pathology by cross-seeding?
Treatment and diagnosis
Can arresting prion-like spreading delay the progression of NDs? Is it possible to use the prion principle to develop a selfpropagating therapy for NDs? Is detection of misfolded oligomers a good target for early diagnosis of NDs? Can the prion principle be used to amplify seeding-competent misfolded oligomers circulating in biological fluids to facilitate their detection?
FOCUS |
Review ARticle https://doi.org/10.1038/s41593-018-0235-9
FOCUS | Review ARticle
Review ARticle | FOCUS NATuRe NeuRosCIeNCe define prions as proteins able to adopt alternative conformations, some of which can self-propagate their folding in an autocatalytic seeding reaction that can be spread between cells and tissues. This definition avoids the need for prions to be necessarily associated with infectious diseases, but captures the essential aspects of this important phenomenon, which represents a new biological framework with potentially important consequences to understand and treat many diseases.
